By Dean Seal
Alzamend Neuro has gotten the go-ahead from federal regulators to launch a clinical study of its treatment for major depressive disorder.
The biopharmaceutical company said Monday that it received a “Study May Proceed” letter from the U.S. Food and Drug Administration for a Phase IIA clinical study of AL001.
“We…
Read the full article here